Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 5/20 | 0.66 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.66 |
| ▸ | KDM1A | O60341 | 5/20 | 0.60 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.54 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.51 |
| ▸ | HTR3A | P46098 | 1/20 | 0.51 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.50 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2240382 | 0.85 | SLC6A2 (0.61) | SLC6A2SLC6A4KDM1ASLC6A3SIGMAR1 | |
| SCHEMBL14577922 | 0.84 | LTA4H (0.56) | SLC6A2SLC6A4KDM1ASLC6A3MAP2K1 | |
| SCHEMBL3163776 | 0.84 | MAP2K1 (0.53) | SLC6A2SLC6A4KDM1ASLC6A3MAP2K1 | |
| SCHEMBL13107024 | 0.84 | MAP2K1 (0.53) | SLC6A2SLC6A4KDM1ASLC6A3MAP2K1 | |
| SCHEMBL3443378 | 0.84 | TDP1 (0.65) | SLC6A2SLC6A4KDM1ASLC6A3MAP2K1 | |
| SCHEMBL13107005 | 0.84 | LTA4H (0.55) | SLC6A2SLC6A4KDM1ASLC6A3MAP2K1 | |
| SCHEMBL12622443 | 0.84 | KDM1A (0.60) | SLC6A2SLC6A4KDM1ASLC6A3MAP2K1 | |
| SCHEMBL3159146 | 0.84 | SLC6A2 (0.62) | SLC6A2SLC6A4KDM1ASLC6A3MAP2K1 | |
| SCHEMBL2267290 | 0.84 | SLC6A2 (0.57) | SLC6A2SLC6A4KDM1ASLC6A3MAP2K1 | |
| SCHEMBL3444195 | 0.84 | SLC6A2 (0.57) | SLC6A2SLC6A4KDM1ASLC6A3MAP2K1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090233910-A1 | Npy antagonists, preparation and uses | CEREP (FR) | 2009-09-17 | — | — | US | disclosed |
| EP-1879887-A2 | NPY ANTAGONISTS, PREPARATION AND USE | Cerep (FR) | 2008-01-23 | — | — | EP | disclosed |
| WO-2006108965-A2 | NPY ANTAGONISTS, PREPARATION AND USE | CEREP (FR) | 2006-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233910-A1 | Npy antagonists, preparation and uses | NPY1R, NPY5R, NPY2R | SLC6A2 331/4885SLC6A4 438/4885KDM1A 2049/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.